SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (6016)3/23/2002 11:20:04 PM
From: LLCF  Respond to of 52153
 
Thanks.

DAK



To: Miljenko Zuanic who wrote (6016)3/24/2002 2:51:09 AM
From: Spekulatius  Read Replies (1) | Respond to of 52153
 
<< CONCLUSIONS: Plasma endostatin levels are elevated in colorectal cancer patients with liver metastases and correlate with VEGF levels. Elevated endostatin levels during follow-up are associated with disease progression. >>

Miljenko, does this mean that endostatin gets produced some where in the cascade of events leading to cancer growth? Could one even argue that endostatin causes or accelerates cancer growth. Even the possibility thereof would kill endostatin as a drug.



To: Miljenko Zuanic who wrote (6016)3/24/2002 11:35:42 AM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
Thanks, Miljenko - I hadn't seen those abstracts.

Folkman's original hypothesis was partly based on the fact that when you surgically remove primary tumors the remaining metastatic tumors tend to dramatically increase in size. Hence he figured that the primary tumor was secreting something that kept the mets in check, and endostatin was one such candidate.

These abstracts are somewhat consistent with that theory - continuing high levels of endostatin perhaps imply that the original tumor is still active. None of these abstracts look at the progression of the mets themselves based on endostatin level - something that would be interesting to see.

Peter